ArticleInternal medicine journal2025
Temporal trends in gender-affirming hormone therapy initiation: evidence from whole-of-population Australian administrative data.
Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cardiometabolic diseases in transgender populations.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Healthcare Costs Following Medical Gender-Affirmation: Evidence From Whole-of-Population Australian Administrative Data.Health economics · 2026Article
- All-cause and cause-specific mortality among transgender and gender diverse people: a nationwide cohort study in Australia.The Lancet regional health. Western Pacific · 2026Article
- Mental health treatment among transgender and gender diverse people following gender affirming hormone therapy: evidence from whole-of-population Australian administrative data.EClinicalMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Using longitudinal national prescribing data, we estimated the number of transgender and gender-diverse individuals initiating gender-affirming hormone therapy (GAHT) from 2013 to 2024 in Australia. Between 2013 and 2024, 11 883 individuals initiated testosterone-based GAHT and 20 358 initiated oestrogen-based GAHT. Initiation rose from 1118 in 2013 to 5135 in 2024, with a growing share accessing testosterone-based GAHT over time. The mean age at initiation also fell from 50 years in 2013 to 26 years in 2024. Our findings align with international trends, suggesting increasing demand among younger populations. This highlights the need for specialised, accessible gender-affirming care in Australia and underscores the importance of improved data collection to inform health policy and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.